In this episode of Teach Me in 10, Ken Neubauer, Principal Application Scientist at PerkinElmer, explains how ICP-OES is used ...
Solriamfetol, a new treatment for ADHD, showed a 45% reduction in symptoms in a Phase 3 trial. This treatment targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback